Aptose Reports First Quarter 2025 Results
Globenewswire·2025-05-08 11:00
Highlights Progress in TUSCANY Clinical Trial of Tuspetinib in AML Triple Frontline TherapySAN DIEGO and TORONTO, May 08, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX: APS and OTC: APTOF), a clinical-stage precision oncology company developing a tuspetinib (TUS)-based triple drug frontline therapy to treat patients with newly diagnosed acute myeloid leukemia (AML), today announced financial results for the first quarter ended March 31, 2025, and provided a corporate upda ...